Debra Morris
Gerontology · Poulsbo, WANPI 1053401117
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,583 of the $2,082 with a category attached, or 76.0%. 14 manufacturers reported payments, led by Incyte Corporation at 50.6% of the total.
Across 37 payments — averaging $56.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$1K
- Amgen$233
- Eisai Inc.$222
- Lilly USA, LLC$123
- Seagen Inc.$100
- Astellas Pharma US Inc$100
- plus $250 from 8 others
What the payments were for
- Food & beverage$1,58376%
- Education$49924%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 20 | $1,054 |
| Amgen | 3 | $233 |
| Eisai Inc. | 2 | $222 |
| Lilly USA, LLC | 1 | $123 |
| Seagen Inc. | 1 | $100 |
| Astellas Pharma US Inc | 1 | $100 |
| AstraZeneca | 2 | $86 |
| Johnson & Johnson | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| AbbVie | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Beigene USA, Inc. | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $19 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,082 in reported general payments places this provider in the 85th percentile of 105 gerontology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 52 | $461 |
| Dexamethasone | 24 | $355 |
| Prochlorperazine Maleate | 40 | $321 |
| Oxycodone Hcl | 24 | $313 |
| Acyclovir | 26 | $302 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $258 |
| Potassium Chloride | 18 | $172 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $130 |
| Prednisone | 11 | $118 |
Paid to pharmacies, not to this prescriber.
Other gerontology in Poulsbo
- Amy WoodruffTacoma$118K
- Peter WilcoxSilverdale$16K
- Kristi ParrisSilverdale$10K
- Samuel GodinSilverdale$7K
- Byron TatschSpokane Valley$4K
- Catherine RehbergerTacoma$4K
- Nachole BrownSeattle$4K
- Si FengRichland$3K
- Shanti Benoit BoyceSeattle$3K
- Elizabeth MyrickSeattle$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.